Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent

Medicinal Chemistry

Volumn 5, Issue 6, 2009, Pages 491-496

  Dell'Antone, P ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

3 bromopyruvate; Glyceraldehyde 3 phosphate dehydrogenase; Glycolysis; Hexokinase; Oxidative phosphorylation; Succinate dehydrogenase; Tumor therapy; Warburg effect

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; BAFILOMYCIN; BROMOPYRUVIC ACID; DEOXYGLUCOSE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEXOKINASE; OLIGOMYCIN; POTASSIUM CYANIDE; PYRUVIC ACID; PYRUVIC ACID DERIVATIVE; SUCCINATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE; GLYCOLYSIS; HEPATOMA CELL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; RAT; THYMOCYTE;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTINEOPLASTIC AGENTS; CYTOSOL; ENERGY METABOLISM; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GLYCOLYSIS; HEXOKINASE; L-LACTATE DEHYDROGENASE; LIVER; MITOCHONDRIA; OXIDATION-REDUCTION; PHOSPHORYLATION; PYRUVATES; RATS; SUCCINIC ACID; THYMUS GLAND;

EID: 75749136104     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340609790170551     Document Type: Article

References (30)

1. Ko, Y.H.; Pedersen, P.L.; Geschwind, J.F. Glucose metabolism in the rabbit VX" tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett., 2001, 173, 83-91.
2. Geschwind, J.F.; Ko, Y.K.; Torbenson, M.S.; Mages, G.; Pedersen, P.L. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res., 2002, 62, 3909-3913.
3. Ko, Y.H.; Smith, B.L.; Wang, L.; Pamper, M.G.; Rini, D.A.; Torbenson, M.S.; Hullihen, J.; Pedersen, P. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res.Comm., 2004, 324, 269-275.
4. Ko, Y.H.; McFadden, B.A. Alkylation of isocitrate lyase from Escherichia coli by 3-bromopyruvate. Arch. Biochem. Biophys., 990, 278, 373-380.
5. Jones, A.R.,; Gillan, L.; Milmlow, D. The anti-glycolytic activity of 3-bromopyruvate on mature boar spermatozoa in vitro. Contraception, 1995, 52, 317-320.
6. Jones, A.R.; Porter, K. E.; Dobbie, M. S. Renal and spermatozoal toxicity of alpha-bromohydrin, 3-bromolactate and bromopyruvate. Appl. Toxicol., 1996, 16, 57-63.
7. Johnson, D.; Lardy, H. Isolation of liver or kidney mitochondria. Methods Enzimol., 1967, 10, 94-96, 413-425.
8. Dell'Antone, P.; Cusinato, O.; Volpato, O. Mechanism of acridine uptake by submitochondrial particles. Arch. Biochem. Biophys., 1978, 191, 413-425.
9. Williamson, J.R.; Corkey, B.E. Assay of the intermediates of the citric acid cycle and related compounds by fluorimetric enzyme methods. Methods Enzymol., 1969, XIII, 488-491.
10. Velick, S.F. Glyceraldehyde-3-phosphate dehydrogenase from muscle. Methods Enzymol., 1955, 1, 401-406.
11. Dell'Antone, P.; Piergallini, L. The antineoplastic drug lonidamine interferes with the acidification mechanism of cell organelles. Biochim. Biophys. Acta, 1997, 1358, 46-52.
12. Dell'Antone, P. Evidence for an ATP-driven proton pump in rat liver lysosomes by basic dye uptake. Biochem. Biophys. Res. Commun., 1979, 86, 180-189.
13. +-vacuolar ATPase by the energy blocker 3-bromopyruvate antitumour agent. Life Sci., 2006, 79, 2049-2055.
14. Warburg, O. The Metabolism of Tumors. Arnold Constable: London (UK) 1930.
15. Guppy, M.; Zu, X.L. Cancer metabolism: facts, fantasy and fiction. Biochem. Biophys. Res. Commun., 2004, 313, 459-465.
16. Moreno-Sanchez, R.; Rodriguez-Enriquez, S.; Marin-Hernandez, A.; Saavedra, E. Energy metabolism in tumor cells. FEBS J., 2007, 274, 1393-1418.
17. Gatenby, R.A.; Gillies, R.J. Glycolysis in cancer: a potential target for therapy. Int. J. Biochem. Cell. Biol., 2007, 39, 1358-1366.
18. Pelicano, H.; Martin, D.X.U.; R.H.; Huang, P. Glycolysis inhibition for anticancer treatment. Oncogen, 2006, 25, 4633-4646.
19. Aft, R.L.; Zhang, F.W.; Gius, D. Evaluation of 2- deoxy-D-glucose as a chemoterapeutic agent: mechanism of cell death. Br. J. Cancer, 2002, 87, 805-812.
20. Chen, Z.; Lu, W.; Garcia-Prieto, C.P.; Huang, P. The Warburg effect and its cancer therapeutic implications. J. Bioenerg. Biomembr., 2007, 39, 267-274.
21. Shaw, R.J. Glucose metabolism and cancer. Curr. Opin. Cell Biol., 2006, 18, 598-608.
22. Geschwind, J.F.; Georgiades, C.S.; Ko, Y.H.; Pedersen, P.L. Recently elucidated energy catabolism pathways provide opportunities for novel treatment in hepatocellular carcinoma. Expert. Rev. Anticancer Ther., 2004, 4, 440-457.
23. Pedersen, P.L.; Mathupala, S.; Rempel, A.; Geschwind, J.F.; Ko, Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic interventions. Biochim. Biophys. Acta, 2002, 1555, 14-20.
24. Murakami, K.; Imamura, Y.; Ishibashy, S. Difference between hexokinase isoenzymes in sensitivity to sulfhydryl inhibitor. J. Biochem., 1973, 74, 175-177.
25. Tiedge, M.; Richter, T.; Lenzen, S. Importance of cysteine residues for stability and catalytic activity of human beta cells glucokinase. Arch. Biochem. Biophys., 2000, 375, 251-260.
26. Parlo, R.A.; Coleman, P.S. Enhanced rate of citrate export from cholesterol-rich hepatoma mitochondria. The truncated Krebs cycle and other metabolic ramifications of mitochondrial membrane cholesterol. J. Biol: Chem., 1984, 259, 9997-10003.
27. Baggetto, L.G. Deviant energy metabolism of glycolytic cancer cells. Biochimie, 1992, 74, 959-974.
28. Piva, T.J.; McEvoy-Bowe, E. Oxidation of glutamine in Hela cells: role and control of truncated TCA cycle in tumour mitohcondria. J. Cell. Biochem., 1998, 68, 213-225.
29. + ATP-ase induce apoptotic cell death. Biochem. Biophys. Res.Commun.,1995, 212, 255-262.
30. +-linked monocarboxylate transporter (MCT1/SLC16A1): a potential target for high risk neuroblastoma. Mol. Pharmacol., 2006, 70(6), 2108-2115.